Actively Recruiting

Phase Not Applicable
Age: 50Years +
All Genders
NCT06557369

A Clinical Trial Evaluating the Safety and Efficacy of a New Light Combination Therapy Addressing Intermediate AMD

Led by Oculox Technologies SA · Updated on 2024-11-15

30

Participants Needed

1

Research Sites

56 weeks

Total Duration

On this page

Sponsors

O

Oculox Technologies SA

Lead Sponsor

L

Latis S.r.l.

Collaborating Sponsor

AI-Summary

What this Trial Is About

The proposed clinical investigation wants primary to validate the safety of the innovative light therapy approach and in second priority provide insight and confirmations on therapeutic effect. By combining two clinically standard laser-light treatment, both exhibiting a solid-safe profile: the photothermal and the photobiological techniques; the investigational device (reSEES) wants to explore a completely new therapeutic approach by synergically take advantage of the inherent and already observed clinical performances of the two independent techniques.

CONDITIONS

Official Title

A Clinical Trial Evaluating the Safety and Efficacy of a New Light Combination Therapy Addressing Intermediate AMD

Who Can Participate

Age: 50Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male and female patients 50 years of age or older
  • Diagnosis of intermediate AMD, Grade AREDS 3
  • Both eyes eligible for the study
  • Willingness to sign informed consent and comply with study procedures
  • Ability to maintain stable dietary supplements and lifestyle habits during study participation
Not Eligible

You will not qualify if you...

  • Myopia greater than 8 diopters
  • Maximum pupil dilation less than 4 mm
  • Planned ocular surgery during the study
  • Clinically significant cataract
  • Ocular surgery within 6 months before study start
  • Previous retinal treatments such as anti-VEGF therapy or laser photocoagulation
  • Diabetic retinopathy
  • Other macular diseases or retinal conditions like retinitis pigmentosa or diabetic macular edema
  • Other eye diseases affecting vision including amblyopia, uncontrolled glaucoma, or media opacity
  • Serious systemic diseases or conditions affecting study participation
  • Pregnancy or breastfeeding
  • Participation in another interventional clinical trial
  • Expected inability to complete the study due to mental health, age, or personal issues
  • Photosensitivity

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Humanitas Castelli

Bergamo, Italy, 24128

Actively Recruiting

Loading map...

Research Team

M

Mario Romano, Prof.

CONTACT

M

Maria Belotti, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here